These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32622719)

  • 21. Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients.
    Fathy MM; Abo Taleb ME; El Hawary MS; Nabih MI; Aref WM; Makhlouf MM
    Cytokine; 2015 Aug; 74(2):268-72. PubMed ID: 26003758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
    Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.
    Halfon P; Bourliere M; Ouzan D; Maor Y; Renou C; Wartelle C; Pénaranda G; Tran A; Botta D; Oules V; Castellani P; Portal I; Argiro L; Dessein A
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):931-5. PubMed ID: 21900787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
    Ogurtsov PP; Kukhareva EI
    Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection.
    Abdelwahab SF; Zakaria Z; Allam WR; Hamdy S; Mahmoud MA; Sobhy M; Rewisha E; Waked I
    Arch Virol; 2015 Nov; 160(11):2833-7. PubMed ID: 26280523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study.
    Kamal SM; Kassim SK; Ahmed AI; Mahmoud S; Bahnasy KA; Hafez TA; Aziz IA; Fathelbab IF; Mansour HM
    Am J Gastroenterol; 2014 Feb; 109(2):199-211. PubMed ID: 24445571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis.
    Rangnekar AS; Fontana RJ
    J Viral Hepat; 2013 Jun; 20(6):377-84. PubMed ID: 23647954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus.
    Wong GL; Chan HL; Tse CH; Chan PO; Cheng JC; Cheng JS; Lau SH; Lee EK; Ma JM; Chan AW; Choi PC; Wong VW
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1040-8. PubMed ID: 25639146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians.
    Zakaria ZA; Knapp S; Hashem M; Zaghla H; Thursz M; Waked I; Abdelwahab S
    Immunol Res; 2019 Feb; 67(1):123-133. PubMed ID: 30402710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.
    Zheng H; Li M; Chi B; Wu XX; Wang J; Liu DW
    Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):576-83. PubMed ID: 25769643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
    Thompson AJ; Muir AJ; Sulkowski MS; Ge D; Fellay J; Shianna KV; Urban T; Afdhal NH; Jacobson IM; Esteban R; Poordad F; Lawitz EJ; McCone J; Shiffman ML; Galler GW; Lee WM; Reindollar R; King JW; Kwo PY; Ghalib RH; Freilich B; Nyberg LM; Zeuzem S; Poynard T; Vock DM; Pieper KS; Patel K; Tillmann HL; Noviello S; Koury K; Pedicone LD; Brass CA; Albrecht JK; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Jul; 139(1):120-9.e18. PubMed ID: 20399780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C.
    Nadia K; Hicham E; Reda TM; Nadia T; Elarbi B; Saâd E; Mimoun Z; Saâd M
    Gene; 2015 Aug; 568(1):31-4. PubMed ID: 25958342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
    Huang CF; Huang JF; Yang JF; Hsieh MY; Lin ZY; Chen SC; Wang LY; Juo SH; Chen KC; Chuang WL; Kuo HT; Dai CY; Yu ML
    J Hepatol; 2012 Jan; 56(1):34-40. PubMed ID: 21703176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.
    Rallón NI; Naggie S; Benito JM; Medrano J; Restrepo C; Goldstein D; Shianna KV; Vispo E; Thompson A; McHutchison J; Soriano V
    AIDS; 2010 May; 24(8):F23-9. PubMed ID: 20389235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
    Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
    World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Genetic polymorphisms of IL-28B are associated with sustained virologic response in patients with chronic hepatitis C].
    Xie JQ; Guo XY; Cao H; Zhang XH; Xie DY; Gao ZL; Zhao ZX
    Zhonghua Gan Zang Bing Za Zhi; 2012 Dec; 20(12):892-5. PubMed ID: 23522248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients.
    Derbala M; Rizk NM; Al-Kaabi S; John A; Sharma M; El-dweik N; Yakoob R; Pasic F; Almohanadi M; Alejji K; Abdelmola A; Butt M
    Virology; 2013 Sep; 444(1-2):292-300. PubMed ID: 23866096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.